Liver Disease and NAFLD: Symptoms, NHS Diagnosis, Treatment and Liver Health Guide

Liver disease is the third most common cause of premature death in the UK, and cases are rising — driven primarily by alcohol-related liver disease, non-alcoholic fatty liver disease (NAFLD), and viral hepatitis. Unlike other major killers, liver disease disproportionately affects younger people. An estimated 1 in 3 adults in the UK has early-stage NAFLD — making it the most common liver condition in the country — yet most people have no idea they have it.

Non-Alcoholic Fatty Liver Disease (NAFLD)

NAFLD is the most common liver condition in the UK, affecting approximately 32% of adults — around 20 million people. It is characterised by excess fat accumulation in the liver (steatosis) in people who drink little or no alcohol. NAFLD exists on a spectrum:

  • Simple steatosis — fat in the liver without significant inflammation; generally stable; can resolve with lifestyle changes
  • NASH (Non-Alcoholic SteatoHepatitis) — fat plus inflammation and liver cell damage; can progress to fibrosis and cirrhosis; affects approximately 5% of UK adults
  • Advanced fibrosis/cirrhosis — scarring of the liver; may progress to liver failure or liver cancer

Note: In 2023, international liver organisations renamed NAFLD to MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) and NASH to MASH. UK NHS guidance is transitioning to this new terminology, though many GPs still use NAFLD/NASH.

Risk Factors for NAFLD

  • Obesity — particularly central (abdominal) obesity; present in 70–80% of NAFLD cases
  • Type 2 diabetes — 70% of people with type 2 diabetes have NAFLD; see our diabetes guide
  • High cholesterol and triglycerides — see our cholesterol guide
  • High blood pressure — see our hypertension guide
  • Insulin resistance and metabolic syndrome
  • Rapid weight loss or starvation
  • Certain medications (tamoxifen, corticosteroids, amiodarone)

Symptoms of NAFLD

NAFLD is typically asymptomatic until advanced liver disease develops. Some people with NASH experience:

  • Fatigue and poor energy
  • Right upper quadrant discomfort (a dull ache under the right ribs)
  • In advanced disease: jaundice (yellowing), abdominal swelling (ascites), easy bruising, confusion (hepatic encephalopathy)

Diagnosis of NAFLD

  • Liver function tests (LFTs) — elevated ALT and AST suggest liver cell damage; but normal LFTs do NOT rule out NAFLD or even significant fibrosis
  • Liver ultrasound — detects fatty liver (echogenic liver); standard first-line imaging; cannot reliably grade fibrosis
  • FIB-4 score — NICE-recommended non-invasive fibrosis assessment tool using age, ALT, AST, and platelet count; stratifies NAFLD patients into low, intermediate, and high fibrosis risk
  • Fibroscan (transient elastography) — measures liver stiffness; non-invasive fibrosis staging; available in liver clinics and increasingly in NHS community settings
  • Liver biopsy — gold standard for staging NASH vs simple steatosis; but invasive; reserved for cases where non-invasive tests are inconclusive

NHS Treatment for NAFLD

Currently, there are no NICE-approved pharmacological treatments specifically for NAFLD/NASH in the UK, though several are in advanced clinical trials:

  • Weight loss — the most effective treatment — losing 7–10% of body weight can significantly reduce liver fat; losing 10% or more can reverse NASH and reduce fibrosis. NICE recommends lifestyle intervention as first-line
  • Exercise — aerobic exercise and resistance training independently reduce hepatic steatosis, even without weight loss
  • Alcohol abstinence — even modest alcohol in NAFLD patients worsens progression; abstinence recommended for those with fibrosis
  • GLP-1 receptor agonists — semaglutide shows promise for NASH; clinical trials show histological improvement; not yet NICE-approved specifically for NAFLD but widely used in people with comorbid type 2 diabetes and obesity; see our Ozempic and Wegovy guide
  • Vitamin E — NICE acknowledges some evidence for NASH in non-diabetic patients; not routinely recommended but sometimes used off-label
  • Resmetirom (Rezdiffra) — thyroid hormone receptor-beta agonist; FDA-approved in USA March 2024 for NASH; NICE assessment pending in UK

Alcohol-Related Liver Disease (ALD)

Alcohol is the leading cause of liver cirrhosis and liver cancer in the UK. The spectrum of ALD includes:

  • Alcoholic fatty liver — develops after even short-term heavy drinking; fully reversible with abstinence
  • Alcoholic hepatitis — acute liver inflammation; severe cases carry 30-day mortality rates of 30–50%
  • Alcoholic cirrhosis — permanent scarring; portal hypertension; risk of variceal bleeding, ascites, and liver cancer

Safe limits: NHS advises no more than 14 units/week for both men and women, spread over 3 or more days. One unit = 10ml pure alcohol = half a pint of 4% beer = a 25ml shot of spirits.

UK Liver Disease Resources

  • British Liver Trust — britishlivertrust.org.uk | Helpline: 0800 652 7330 | UK’s leading liver disease charity
  • NHS Alcohol Support — nhs.uk/live-well/alcohol-advice | Free resources and referrals
  • Alcohol Change UK — alcoholchange.org.uk | Support for reducing alcohol use
  • NICE NG49 — Non-alcoholic fatty liver disease: assessment and management

What Major Health Sites Often Miss About Liver Disease

1. FIB-4 Scoring: The NHS’s Non-Invasive Fibrosis Tool

NICE recommends the FIB-4 score as a non-invasive, simple blood-test-based tool to assess liver fibrosis risk in all NAFLD patients in primary care. A FIB-4 below 1.30 indicates low risk (90% negative predictive value for advanced fibrosis), above 2.67 indicates high risk requiring specialist referral. Most US health sites don’t mention this UK-endorsed tool that is transforming NAFLD management in NHS primary care, allowing appropriate stratification without liver biopsy in most patients.

2. NAFLD Affects 1 in 3 UK Adults — Most Completely Unaware

The scale of NAFLD in the UK is extraordinary — 32% of adults have fatty liver, yet it is almost always silent. Because liver function tests can be normal even with significant fibrosis, many people with advanced NAFLD are only identified incidentally through routine imaging. People with type 2 diabetes, obesity, or metabolic syndrome should ask their GP specifically whether their liver has been assessed, including a FIB-4 score calculation.

Related Health Guides on YourHealthXpert